XML 73 R51.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Segment Reporting (Details) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012
Summary of segment information |  |  |  |  |  |  |  |  |  |  |
Total Assets | $ 258,029us-gaap_Assets |  |  |  | $ 104,713us-gaap_Assets |  |  |  | $ 258,029us-gaap_Assets | $ 104,713us-gaap_Assets |
Net revenues from external customers | 22,999us-gaap_Revenues | 14,973us-gaap_Revenues | 10,608us-gaap_Revenues | 15,958us-gaap_Revenues | 14,737us-gaap_Revenues | 13,005us-gaap_Revenues | 9,580us-gaap_Revenues | 11,651us-gaap_Revenues | 64,538us-gaap_Revenues | 48,973us-gaap_Revenues | 31,388us-gaap_Revenues
Operating (loss) income |  |  |  |  |  |  |  |  | 19,626us-gaap_OperatingIncomeLoss | 14,943us-gaap_OperatingIncomeLoss | 193us-gaap_OperatingIncomeLoss
Depreciation and amortization expense |  |  |  |  |  |  |  |  | 2,657us-gaap_DepreciationDepletionAndAmortization | 2,663us-gaap_DepreciationDepletionAndAmortization | 2,727us-gaap_DepreciationDepletionAndAmortization
Write-off of in-process research and development |  |  |  |  |  |  |  |  |  | 480lgnd_WriteoffofInProcessResearchandDevelopment |
Income tax (expense) benefit | (280)us-gaap_IncomeTaxExpenseBenefit | (124)us-gaap_IncomeTaxExpenseBenefit | 47us-gaap_IncomeTaxExpenseBenefit | (53)us-gaap_IncomeTaxExpenseBenefit | (138)us-gaap_IncomeTaxExpenseBenefit | (60)us-gaap_IncomeTaxExpenseBenefit | (110)us-gaap_IncomeTaxExpenseBenefit | (66)us-gaap_IncomeTaxExpenseBenefit | (410)us-gaap_IncomeTaxExpenseBenefit | (374)us-gaap_IncomeTaxExpenseBenefit | 1,191us-gaap_IncomeTaxExpenseBenefit
Interest expense, net |  |  |  |  |  |  |  |  | 4,860us-gaap_InterestExpense | 2,077us-gaap_InterestExpense | 2,924us-gaap_InterestExpense
Gain on sale of Avinza Product Line before income taxes |  |  |  |  |  |  |  |  | 0us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax | 2,588us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax | 3,656us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
Income tax expense from discontinuing operations |  |  |  |  |  |  |  |  |  |  | (1,509)us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
Ligand |  |  |  |  |  |  |  |  |  |  |
Summary of segment information |  |  |  |  |  |  |  |  |  |  |
Total Assets | 184,215us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember |  |  |  | 38,408us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember |  |  |  | 184,215us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 38,408us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember |
Net revenues from external customers |  |  |  |  |  |  |  |  | 27,174us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 21,436us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 19,582us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Operating (loss) income |  |  |  |  |  |  |  |  | (2,372)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 253us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | (919)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Depreciation and amortization expense |  |  |  |  |  |  |  |  | 253us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 233us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 222us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Write-off of in-process research and development |  |  |  |  |  |  |  |  |  | 0lgnd_WriteoffofInProcessResearchandDevelopment / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember |
Income tax (expense) benefit |  |  |  |  |  |  |  |  | 5,106us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | (419)us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 1,096us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Interest expense, net |  |  |  |  |  |  |  |  | 4,860us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 2,077us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 2,924us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Gain on sale of Avinza Product Line before income taxes |  |  |  |  |  |  |  |  |  | 2,588us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember | 3,656us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
Income tax expense from discontinuing operations |  |  |  |  |  |  |  |  |  |  | (1,509)us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation / us-gaap_StatementBusinessSegmentsAxis = lgnd_LigandMember
CyDex |  |  |  |  |  |  |  |  |  |  |
Summary of segment information |  |  |  |  |  |  |  |  |  |  |
Total Assets | 73,814us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember |  |  |  | 66,305us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember |  |  |  | 73,814us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 66,305us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember |
Net revenues from external customers |  |  |  |  |  |  |  |  | 37,364us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 27,537us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 11,806us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Operating (loss) income |  |  |  |  |  |  |  |  | 21,998us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 14,690us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 1,112us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Depreciation and amortization expense |  |  |  |  |  |  |  |  | 2,404us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 2,430us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 2,505us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Write-off of in-process research and development |  |  |  |  |  |  |  |  |  | 480lgnd_WriteoffofInProcessResearchandDevelopment / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember |
Income tax (expense) benefit |  |  |  |  |  |  |  |  | (5,516)us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 45us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 95us-gaap_IncomeTaxExpenseBenefit / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Interest expense, net |  |  |  |  |  |  |  |  | 0us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 0us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 0us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Gain on sale of Avinza Product Line before income taxes |  |  |  |  |  |  |  |  |  | 0us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember | 0us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember
Income tax expense from discontinuing operations |  |  |  |  |  |  |  |  |  |  | $ 0us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation / us-gaap_StatementBusinessSegmentsAxis = lgnd_CydexPharmaceuticalsIncMember

X
- Definition Write-off of In-Process Research and Development + References No definition available. + Details
Name: | lgnd_WriteoffofInProcessResearchandDevelopment
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 + Details
Name: | us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Tax effect allocated to a disposal group that is classified as a component of the entity reported as a separate component of income before extraordinary items. Includes the tax effects of the following: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b),(c) -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e38679-109324 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759 + Details
Name: | us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 + Details
Name: | us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 + Details
Name: | us-gaap_InterestExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lgnd_CydexPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lgnd_LigandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |